BioCentury | Sep 15, 2020
Finance

Sept. 14 Quick Takes: $70M+ rounds for Escient, Escape, plus Alzheimer’s data lifts Cassava shares and more

...to bring the MRGPRX4-targeting program through Phase II; and advance its second program, which targets MRGPRX2...
BioCentury | Jan 8, 2019
Distillery Therapeutics

Infectious disease

...INDICATION: Staphylococcus Cell culture and mouse studies suggest the MRGPRX2 activator mastoparan could help treat Staphylococcus...
...Staphylococcus aureus skin infection. In cell-based gene reporter assays, the wasp venom toxin mastoparan activated MRGPRX2-mediated...
...Next steps could include testing mastoparan in models with other S. aureus -infected tissues. TARGET/MARKER/PATHWAY: MAS-related GPR member X2 (MRGPRX2)...
BioCentury | May 9, 2018
Financial News

Column Group leads Escient's $40M series A

Escient Pharmaceuticals Inc. (San Diego, Calif.) raised $40 million in a series A round led by The Column Group. Also participating were 5AM Ventures and Osage University Partners. Escient is developing compounds targeting GPCRs, including...
BioCentury | Jan 29, 2015
Distillery Therapeutics

Therapeutics: MAS-related GPR member X2 (MRGPRX2)

...Inflammation INDICATION: Allergy Mouse studies suggest inhibiting MRGPRX2 could help prevent drug-induced pseudo-allergic reactions, which do...
...could help prevent drug-induced pseudo-allergic reactions, which do not involve IgE. In mast cells from MRGPRX2-knockout...
...MRGPRX2 knockout decreased pseudo-allergic effects compared with normal MRGPRX2 expression. Next steps include developing an MRGPRX2...
BioCentury | Jan 22, 2015
Targets & Mechanisms

Pseudo-allergy exposed

...to findings from a group at Johns Hopkins University that showed the mast cell protein MRGPRX2...
...patent has been filed by Johns Hopkins University covering MRGPRX2 as a screening modality and MRGPRX2-expressing...
...reactions by stimulating the mast cell receptor MRGPRX2. The cyclized monomer of 48/80, a potent MRGPRX2...
BioCentury | Aug 21, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer G protein q polypeptide (GNAQ) (G-ALPHA-q); MAS-related GPR member X1 (MRGPRX1; GPCR; SNSR4) In vitro and cell culture studies suggest the small molecule compound...
BioCentury | Jan 14, 2010
Distillery Therapeutics

Indication: Dermatology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Dermatitis MAS-related GPR, member X1 (MRGPRX1; SNSR4) A study in mice and in cell culture suggests that antagonizing MRGPRX1 could help treat itching caused by...
BioCentury | Mar 5, 2007
Tools & Techniques

Predicting active peptides

...activated by the eight peptides: MAS1 oncogene (MAS1), MAS-related GPR member X-1 ( MRGPRX1 ), MRGPRX2...
...of the renin-angiotensin pathway, which is implicated in cardiovascular diseases such as hypertension. MRGPRX1 and MRGPRX2...
Items per page:
1 - 8 of 8